learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
5 / 801 resultslearn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
learn PTD-DBM
learn vitamin d2
learn Setipiprant
Research
5 / 95 results
research Hair Growth-Promoting Effects of a Multi-Targeted Cosmetic Formulation Containing PYGL, DP2, and 15-PGDH Inhibitors Developed Using AI-Based DeepZema® in Androgenetic Alopecia: A 24-Week Randomized Controlled Trial
The formulation significantly increased hair density and thickness safely in people with androgenetic alopecia.
research Pathogenic Mechanisms and Mechanism‐Directed Therapies for Androgenetic Alopecia: Current Understanding and Future Directions
Targeting multiple pathways may improve treatments for androgenetic alopecia.
research The physiological and pharmacological roles of prostaglandins in hair growth
Targeting the PGD2-DP2 pathway may help treat hair loss.
research Prostaglandin D2-Mediated DP2 and AKT Signal Regulate the Activation of Androgen Receptors in Human Dermal Papilla Cells
PGD2 increases androgen receptor activity in hair cells, which could be targeted to treat hair loss.
research Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review
Certain drugs are effective for skin conditions like psoriasis, vitiligo, and hair loss.
Community Join
5 / 1000+ resultscommunity Does anyone know of the actual effectiveness of the DP2 inhibitors?
Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.
community Treating my DUPA via controlling inflammation
The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.
community Oral PTD-DBM available online, worth giving a shot?
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community VDPHL01 phase-2/3 results comparison
The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.